Sehifenadin
When ATH:
R06AX
Pharmacological action.
Gistaminovыh blocker H1– receptors; moderately blocks serotonin HT1-receptors, thus, Relaxing effect of mediators of allergy and histamine Serotonin. It has protivogistaminnoe action, not only blocking the histamine H1– receptors, and reducing histamine content in tissues by accelerating its destruction diamine.
It prevents or reduces spazmogennoe influence of histamine and serotonin in the smooth muscles of the bronchi, GI, vessels; violation of capillary permeability and edema development.
It has a pronounced and prolonged effect antipruritic and antiexudative.
It affects the immune reactivity, reducing the amount of antibody and the rosette-forming cells in the spleen, bone marrow, lymph nodes, and also reduces the concentration of immunoglobulins A and G.
Slightly cross the BBB, which explains the absence of pronounced inhibitory effect on the CNS, however, in some cases it may be observed sedation.
Typically, the therapeutic effect occurs within 3 days after initiation of treatment.
Pharmacokinetics
After intake of rapidly absorbed from the gastrointestinal tract. Tmax – 1-2 no. Predominantly accumulates in the lungs, liver, lowest concentration – brain. It is metabolized by oxidation, obrazovaniem with pharmacologically neaktivnogo metabolite.
After administration of a single dose of 50 mg T1/2 – 12 no, and after application of repeated doses – 5.8 no, Not accumulates in the body. 50% dose excreted in bile, more 20% – urine. About 30% the dose is excreted unchanged, 40-50% as metabolites.
Testimony
Allergic rhinitis and conjunctivitis, pollen disease, hives, angioedema, itchy allergic dermatitis, incl. atopic dermatitis.
Dosage regimen
Inside of 50-100 mg 2-3 times / day. A course of treatment – 5-15 days.
Side effect
From the digestive system: dry mouth, epigastric pain, dyspepsia, increased appetite.
CNS: headache, drowsiness; more frequently when used in high doses – excitation, insomnia.
Other: rarely – leukopenia, menstrual irregularities, increased urination.
Contraindications
Simultaneous reception of MAO inhibitors, bronchial asthma, pregnancy, lactation, Age to 18 years, senium (senior 70 years), Hypersensitivity to sehifenadinu.
Cautions
To apply caution in patients with hepatic and / or renal insufficiency.
In most cases, drowsiness decreases or disappears through 2-5 day from the treatment beginning.
Effects on ability to drive vehicles and management mechanisms
Patients, whose work requires high concentration and speed of psychomotor reactions (incl. vehicle drivers), in the period of treatment should refrain from driving vehicles and Occupation potentially hazardous activities.
Drug Interactions
The data is not provided
